Cancer Control Following Polypectomy

NCT00591279•Memorial Sloan Kettering Cancer Center

View on ClinicalTrials.gov

Summary

This study evaluates strategies for the surveillance of post-polypectomy patients for the control of bladder cancer

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•referral for colonoscopy or
•referral for proctoscopy or for a complete colonoscopy after a proctoscopy or flexible sigmoidoscopy

Exclusion Criteria

•prior history of colon cancer, unrelated polypectomy, inflammatory bowel disease, family history of familial polyposis

Locations (1)

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Key Dates

Start Date

February 1, 1981

Primary Completion Date

January 1, 2017

Completion Date

January 1, 2017

Last Updated

September 13, 2023

Enrollment

110

ACTUAL participants

Conditions

Colon Cancer

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

RECRUITINGNA

Resilience and Equity in Aging, Cancer, and Health (REACH)

NCT04674267

Gastric CancerColon Cancer+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 13, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Cancer Control Following Polypectomy

Inclusion Criteria

Exclusion Criteria

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Resilience and Equity in Aging, Cancer, and Health (REACH)

Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation

Phase II Trial of Lung Chemoemobolization

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression